Outlook Therapeutics: Underperform. The approval is real, but the next raise comes first

LYTENAVA is approved and the market values it at about $97 million. We think Outlook must sell more stock at a discount before US sales can prove the launch, so we rate the shares Underperform.

OTLK Underperform: the drug has value, but we expect a discounted equity raise to come before the US launch can show results.

Rating: Underperform Medium conviction
Horizon: 12 months, relative to US-listed biotech stocks
Price basis: $0.5133 on Oct 26, 2026, Nasdaq closing price (Stock Titan quote page)

The call in brief

The approval and 12 years of exclusivity give LYTENAVA real value, and the market prices it at only about $97 million.
Cash net of the Atlas note covers about two quarters on our arithmetic, so a new equity raise is likely before US sales prove anything.
That raise would likely price below today's level, with about 97.2 million warrant shares already struck above the market.

How our ratings work

We rate Outlook Therapeutics Underperform, with medium conviction, over the next 12 months. The rating is set against the Nasdaq close of $0.5133 on October 26, 2026. The FDA approval in July is real and the drug may well find buyers. Our problem is the order of events. Outlook has to raise money again before US sales can show whether the launch works, and on our arithmetic that raise comes within about two quarters, at a price that has already fallen by about half since the last one. We expect the next financing, not the first sales, to set the share price.

How we got here

The product is worth something. On July 24, 2026, the FDA approved LYTENAVA (bevacizumab-vikg) for wet age-related macular degeneration, per an 8-K filed that day. The June quarter 10-Q says the approval carries 12 years of regulatory exclusivity and that off-label repackaged bevacizumab accounts for about 2.7 million injections a year in the US. This is the bull case, and we do not dismiss it. The road to it was rough, as the regulatory record below shows.
The only sales record so far is weak. In Europe, shipments fell to 750 units in the June 2026 quarter from 9,000 a year before, and net revenue for the nine months was negative $1.1 million after a returns charge. That tells us demand has to be built, not assumed.
The cash does not reach the evidence. We estimate about $28 million of cash net of the Atlas note at September 30 (arithmetic below). At recent burn, that funds about two quarters. The company's own guidance is cash into the second quarter of 2027, and the 10-Q carries a going-concern warning.
The next raise is likely to be priced low. Investors paid a combined $0.99 per share and warrant in August. The stock closed at $0.5133 on October 26, about 48% lower. Warrants on about 104.2 million shares are outstanding, and about 97.2 million of them are struck above the market. A fresh deal would almost certainly come at a discount to the current price.
Two deadlines fall before the data. The Atlas note matures on June 16, 2027, and Nasdaq gives Outlook until March 24, 2027 to lift its bid price. Both arrive before two full quarters of US sales can be reported.
So: the stock is cheap against the size of the opportunity, but we think it gets cheaper per share before that opportunity is tested. That is an Underperform. If we are wrong, it will be because a partner or early US demand changes step 3.

The European record

LYTENAVA went on sale in Germany and the UK in June 2025, and Austria followed in 2026. In the June 2026 quarter, net revenue was $8,700, against $1.5 million a year earlier. The year-ago quarter was the launch quarter and likely held the first channel stocking, so the fall overstates the decline. Even so, the MD&A attributes the negative nine-month revenue mainly to a $1.1 million increase in the UK returns reserve plus wholesaler fees, after sell-through missed forecast.

Europe has different pricing and buyers, so we use it only as the one hard data point on sales speed.

The regulatory record

Approval came late. The June quarter 10-Q says NORSE EIGHT, the second trial the FDA required, did not meet its pre-specified non-inferiority endpoint in November 2024. The FDA then issued a second complete response letter on August 27, 2025, citing a lack of substantial evidence of effectiveness, and a third on December 31, 2025. The company took the dispute to the FDA's deciding official in April 2026, and approval followed on July 24. The 10-Q calls the safety profile favorable, the company's word, and we did not review the label's warnings. The accumulated deficit is $653.5 million and stockholders' deficit $10.4 million. Doctors already use repackaged bevacizumab off-label in about 2.7 million US injections a year, so Outlook has to persuade them to switch.

Cash and runway, with the arithmetic

Outlook held $11.2 million of cash and cash equivalents at June 30, 2026. The August offering added net proceeds of about $51.1 million, per the 10-Q. That is about $62.3 million.

Operating cash burn averaged about $14.0 million a quarter over the four quarters to June 2026, and the June quarter alone used $21.0 million. If the September quarter ran at the average, cash at September 30 was about $48.3 million.

Against that sits the March 2026 note to Atlas Sciences: $20.3 million of principal, interest and exit fees at June 30, maturing June 16, 2027. Atlas may redeem up to $3 million a quarter from the six-month mark, and each cash payment carries a 7.5% exit fee. Net of the note, we estimate about $28.0 million. At $14.0 million a quarter, that is two quarters. At $21.0 million, it is less than two. The company guides to cash into the second quarter of 2027, per the August prospectus supplement, and says that estimate rests on assumptions that may prove wrong.

Chief Financial Officer Lawrence Kenyon stepped down effective September 1, 2026, and the board appointed Kevin Lundquist, per an 8-K filed August 27.

Dilution so far, and what is stacked above the price

Shares outstanding went from 33.6 million in May 2025 to 243.4 million in August 2026, on the cover pages of the 10-Qs and 10-K. A May 2025 holder now owns about one seventh of the stake they had. The March 2026 offering priced at $0.25 per share and warrant. The August offering sold 55.6 million shares with an equal number of five-year warrants at a combined $0.99, per the August 14 8-K.

At June 30 there were warrants on 40,353,913 shares outstanding, and the August deal added warrants on up to 63,888,889 more at $1.10. That is about 104.2 million shares under warrant, against 243.4 million outstanding. About 7.1 million of them carry strikes of $0.25 to $0.31 and are below the October 26 close; the other 97.2 million are above it. The $1.10 warrants are struck at more than twice the October 26 close, so they bring in no cash at today's price.

What the price already assumes

	Amount
Shares outstanding (10-Q cover, August 14, 2026)	243,447,554
Market value at $0.5133	about $125.0 million
Our estimate of cash at September 30, 2026	about $48.3 million
Less the Atlas note at June 30, 2026	$20.3 million
Net cash, our estimate	about $28.0 million
Value the market puts on LYTENAVA	about $97 million

To give that number scale, Outlook set a wholesale acquisition cost of $485 per vial, per an 8-K filed September 18. If LYTENAVA took 1% of the 2.7 million US injections at one vial each, that is 27,000 vials, or about $13.1 million a year at list price. At 5% it is 135,000 vials, or about $65.5 million. Net prices will be lower. On those numbers, about $97 million for an approved drug with 12 years of exclusivity does not look expensive. We think the market is pricing the financing, and so are we.

Bull case, bear case

Bull case (30%). US retina doctors take to an approved, on-label bevacizumab quickly, payers cover it, and the first two quarters of sales show it. A commercial partner pays cash up front for the US or for markets outside it; the 10-Q says talks outside the US are ongoing. The next raise is smaller and priced higher than we expect. In this case the shares could do much better than other biotech stocks, from a low base.

Bear case (70%). The launch is slow, as it was in Europe. Outlook raises equity in the first half of 2027 at a discount, likely with more warrants, and does a reverse split to meet the Nasdaq rule. Atlas takes cash each quarter. Per-share value falls even if the business slowly grows.

We weight the bear case more because it only needs the next six months to look like the last 18. The bull case needs several things to go right at once, and soon.

Catalysts

10-K for the fiscal year ended September 30, 2026. Real cash at year end, any Atlas redemptions, and the first statement of US launch plans in an annual report.
US launch, planned before December 31, 2026. The first US unit and revenue figures follow in the December quarter 10-Q.
Nasdaq deadline, March 24, 2027. A reverse split, or a request for a second 180-day period, per the September 30 8-K.
Atlas note maturity, June 16, 2027.
Any partnership for LYTENAVA, inside or outside the US.

Risks to our rating

We would move to Neutral on a partner deal with meaningful cash up front, or if US sales in the first two quarters clearly beat the European run rate. We would move to Outperform if Outlook funded the launch to cash-flow break-even without another discounted equity raise. The rating would also need a fresh look if the stock rose more than 25% from our price basis before the next raise.

This is our opinion as of October 28, 2026, set against a share price of $0.5133 on October 26, 2026. It is not personal investment advice.

Sources

Every figure comes from the documents above. Chart values come from the company's financial statements as tagged in its SEC filings; derived values are labelled. If you find an error, tell us.